Grants and Contributions:

Title:
816022
Agreement Number:
816022
Agreement Value:
$93,848,000.00
Agreement Date:
May 17, 2021 - Jan 1, 2054
Description:
This project will enhance Canada's biomanufacturing capabilities through expansion of aseptic fill-finish capacity, upgrades to critical manufacturing systems, and implementation of digital technologies at Resilience's Mississauga facility. The project’s work phase is scheduled to end on March 31, 2029.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:

The investment will allow the company to add mammalian cell culture (MCC), messenger ribonucleic acid (mRNA) and fill-finish capacity at a single site, including early development capabilities, in a digitally updated facility. It will increase manufacturing footprint and capabilities, improve operational efficiency, and strengthen Canada's ability to develop and manufacture innovative biologic medicines from clinical development through commercial production.

Location:
Mississauga, Ontario, CA L5N8H9
Reference Number:
033-2021-2022-Q1-816022
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
720950070
Recipient Type:
For-profit organization
Additional Information:

The amendment provides for a 60 month extension. The contribution value was reduced to $93,848,000.

Amendment Date
May 14, 2026
Recipient's Operating Name:
Resilience Biotechnologies Inc.
Recipient's Legal Name:
Resilience Biotechnologies Inc.
Federal Riding Name:
Mississauga--Streetsville
Federal Riding Number:
35063
Program:
SIF Stream 2 - Growth
Program Purpose:

Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code:
325410
Amendments: